Your session is about to expire
← Back to Search
Wavefront-guided vs. Optimized LASIK for Myopia
Study Summary
This trial is comparing the outcomes of two different types of LASIK surgery in patients with nearsightedness with and without astigmatism.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am 21 or older with healthy eyes.I am under 21 years old.My corneas are very thin.I have been diagnosed with keratoconus.I have an eye condition where my eye shape is abnormal.
- Group 1: iDesign WFG LASIK
- Group 2: Wavelight WFO LASIK
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Am I eligible to enroll in this medical research?
"This study is accepting applicants who suffer from nearsightedness and are between 21 and 60 years old. Up to a hundred individuals will be included in the trial."
Are researchers currently recruiting participants for this study?
"Sadly, the clinical trial is not presently recruiting. It was initially posted on October 1st 2015 and last updated November 6th 2021. Though this specific study has concluded its recruitment phase, 129 other trials are actively searching for participants now."
Does the trial have any age restrictions, particularly for individuals over 25?
"The accepted age range for participants in this experiment is 21 to 60 years old."
What risks may be associated with undergoing iDesign WFG LASIK surgery?
"The safety rating for iDesign WFG LASIK is quite high, receiving a score of 3. This treatment has been approved as it has moved through Phase 4 trials."
Share this study with friends
Copy Link
Messenger